BR112016030950A2 - polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. - Google Patents
polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira.Info
- Publication number
- BR112016030950A2 BR112016030950A2 BR112016030950A BR112016030950A BR112016030950A2 BR 112016030950 A2 BR112016030950 A2 BR 112016030950A2 BR 112016030950 A BR112016030950 A BR 112016030950A BR 112016030950 A BR112016030950 A BR 112016030950A BR 112016030950 A2 BR112016030950 A2 BR 112016030950A2
- Authority
- BR
- Brazil
- Prior art keywords
- factor viii
- modified
- polypeptide
- complex
- vwf
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/36—Blood coagulation or fibrinolysis factors
- A61K38/37—Factors VIII
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/76—Albumins
- C07K14/765—Serum albumin, e.g. HSA
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
a presente invenção provê um polipeptídeo modificado que se liga ao fator viii. o polipeptídeo modificado compreende uma sequência como definida na seq id no: 3 em que a sequência compreende pelo menos uma modificação na posição 1 ou 3, de modo que o polipeptídeo modificado se liga ao fator viii com uma taxa de dissociação pelo menos 5 vezes menor que um polipeptídeo de referência que compreende uma seq id no: 3 não modificada.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2014902532A AU2014902532A0 (en) | 2014-07-02 | Modified von willebrand factor | |
| PCT/AU2015/050369 WO2016000039A1 (en) | 2014-07-02 | 2015-07-02 | Modified von willebrand factor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112016030950A2 true BR112016030950A2 (pt) | 2018-03-27 |
Family
ID=55018159
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112016030950A BR112016030950A2 (pt) | 2014-07-02 | 2015-07-02 | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US10253088B2 (pt) |
| EP (1) | EP3164150B1 (pt) |
| JP (1) | JP6676551B2 (pt) |
| KR (1) | KR20170026580A (pt) |
| CN (1) | CN106659771B (pt) |
| AU (1) | AU2015283822B2 (pt) |
| BR (1) | BR112016030950A2 (pt) |
| CA (1) | CA2953593C (pt) |
| DK (1) | DK3164150T3 (pt) |
| ES (1) | ES2844232T3 (pt) |
| WO (1) | WO2016000039A1 (pt) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN108779165B (zh) | 2016-01-07 | 2022-12-02 | 康诺贝林伦瑙有限公司 | 突变的冯·维勒布兰德因子 |
| RU2018128582A (ru) * | 2016-01-07 | 2020-02-11 | Цсл Беринг Ленгнау Аг | Мутированный укороченный фактор фон виллебранда |
| EP3538134B1 (en) | 2016-11-11 | 2021-12-29 | CSL Behring Lengnau AG | Truncated von willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder |
| DK3538133T3 (da) | 2016-11-11 | 2021-04-19 | CSL Behring Lengnau AG | Trunkeret von willebrand faktor polypeptider til behandling af hæmofili |
| CA3068098A1 (en) | 2017-06-22 | 2018-12-27 | CSL Behring Lengnau AG | Modulation of fviii immunogenicity by truncated vwf |
| TW202015723A (zh) | 2018-05-18 | 2020-05-01 | 美商百歐維拉提夫治療公司 | 治療ａ型血友病的方法 |
| WO2021001522A1 (en) | 2019-07-04 | 2021-01-07 | CSL Behring Lengnau AG | A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii |
| US20220348637A1 (en) | 2019-11-11 | 2022-11-03 | CSL Behring Lengnau AG | Polypeptides for inducing tolerance to factor viii |
Family Cites Families (36)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4970300A (en) | 1985-02-01 | 1990-11-13 | New York University | Modified factor VIII |
| FR2673632A1 (fr) | 1991-03-08 | 1992-09-11 | Lille Transfusion Sanguine | Procede de preparation de concentre de facteur von willebrand humain de tres haute purete, approprie a un usage therapeutique. |
| AU6029594A (en) | 1993-01-15 | 1994-08-15 | Enzon, Inc. | Factor viii - polymeric conjugates |
| EP0683389A1 (en) | 1994-05-12 | 1995-11-22 | Kabushiki Kaisha Toshiba | Laminograph and inspection and repair device using the same |
| JPH07306165A (ja) | 1994-05-12 | 1995-11-21 | Toshiba Corp | Ｘ線検査装置およびｘ線検査補修装置 |
| DE4435485C1 (de) | 1994-10-04 | 1996-03-21 | Immuno Ag | Verfahren zur Gewinnung von hochreinem von Willebrand-Faktor |
| EP0793504B1 (en) | 1994-12-12 | 2005-06-08 | Beth Israel Deaconess Medical Center, Inc. | Chimeric cytokines and uses thereof |
| AU6455896A (en) | 1995-07-11 | 1997-02-10 | Chiron Corporation | Novel factor viii:c polypeptide analogs with altered metal-binding properties |
| SE9503380D0 (sv) | 1995-09-29 | 1995-09-29 | Pharmacia Ab | Protein derivatives |
| EP0910628B1 (en) | 1996-04-24 | 2006-03-08 | The Regents of The University of Michigan | Inactivation resistant factor viii |
| US20040092442A1 (en) | 1996-04-24 | 2004-05-13 | University Of Michigan | Inactivation resistant factor VIII |
| PT1079805E (pt) | 1998-04-27 | 2005-03-31 | Opperbas Holding Bv | Composicao farmaceutica compreendendo factor viii e lipossomas neutros |
| US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
| AU2002248329B2 (en) | 2001-01-12 | 2007-06-28 | The American National Red Cross | Methods and compositions for reducing heparan sulfate proteoglycan-mediated clearance of factor VIII |
| AU2002310438B2 (en) | 2001-06-14 | 2008-05-01 | The Scripps Research Institute | Stabilized proteins with engineered disulfide bonds |
| EP1572936A2 (en) | 2002-03-05 | 2005-09-14 | Eli Lilly And Company | Heterologous g-csf fusion proteins |
| ES2343681T3 (es) | 2002-04-29 | 2010-08-06 | Stichting Sanquin Bloedvoorziening | Antagonistas de interaccion de factor viii con una proteina relacionada con el receptor de lipoproteinas de baja densidad. |
| CN1698200A (zh) | 2003-02-19 | 2005-11-16 | 日立化成工业株式会社 | 半导体用粘着薄膜 ,使用该粘着薄膜的附有粘着薄膜金属板 ,附有该粘着薄膜的配线电路及半导体装置 ,以及半导体装置的制造方法 |
| LT1596887T (lt) | 2003-02-26 | 2022-04-25 | Nektar Therapeutics | Polimero-faktoriaus viii fragmento konjugatai |
| TWI353991B (en) | 2003-05-06 | 2011-12-11 | Syntonix Pharmaceuticals Inc | Immunoglobulin chimeric monomer-dimer hybrids |
| ES2333598T5 (es) | 2003-05-06 | 2013-09-04 | Biogen Idec Hemophilia Inc | Proteinas quimericas del factor de coagulacion fc para tratar la hemofilia. |
| JP4629047B2 (ja) | 2003-06-12 | 2011-02-09 | イーライ リリー アンド カンパニー | Ｇｌｐ−１アナログ複合タンパク質 |
| JP2008504008A (ja) | 2003-12-31 | 2008-02-14 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフトング | 改良された薬物動態を有するＦｃ−エリスロポエチン融合タンパク質 |
| US7670595B2 (en) | 2004-06-28 | 2010-03-02 | Merck Patent Gmbh | Fc-interferon-beta fusion proteins |
| MX350293B (es) | 2004-11-12 | 2017-09-04 | Bayer Healthcare Llc | Modificacion dirigida al sitio del factor viii. |
| US7884075B2 (en) | 2004-12-27 | 2011-02-08 | Baxter International Inc. | Polymer-factor VIII-von Willebrand factor-conjugates |
| EP1874815A1 (en) | 2005-04-14 | 2008-01-09 | CSL Behring GmbH | Modified coagulation factor viii with enhanced stability and its derivates |
| EP1816201A1 (en) | 2006-02-06 | 2007-08-08 | CSL Behring GmbH | Modified coagulation factor VIIa with extended half-life |
| KR20080108147A (ko) | 2006-03-31 | 2008-12-11 | 백스터 인터내셔널 인코포레이티드 | 페질화된 인자 ｖｉｉｉ |
| WO2007144173A1 (en) | 2006-06-14 | 2007-12-21 | Csl Behring Gmbh | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| WO2008077616A1 (en) | 2006-12-22 | 2008-07-03 | Csl Behring Gmbh | Modified coagulation factors with prolonged in vivo half-life |
| EP2222329A1 (en) * | 2007-11-09 | 2010-09-01 | Baxter International Inc. | Modified recombinant factor viii and von willebrand factor and methods of use |
| AR070141A1 (es) * | 2008-01-23 | 2010-03-17 | Glenmark Pharmaceuticals Sa | Anticuerpos humanizados especificos para el factor von willebrand |
| KR101507718B1 (ko) * | 2008-06-24 | 2015-04-10 | 체에스엘 베링 게엠베하 | 연장된 생체내 반감기를 갖는 인자 ｖｉｉｉ, 폰 빌레브란트 인자 또는 이들의 복합체 |
| LT2804623T (lt) * | 2012-01-12 | 2019-12-10 | Bioverativ Therapeutics Inc | Chimeriniai viii faktoriaus polipeptidai ir jų panaudojimas |
| PL2814502T3 (pl) | 2012-02-15 | 2018-02-28 | Csl Behring Gmbh | Warianty czynnika von Willebranda mające ulepszone powinowactwo do wiązania czynnika VIII |
-
2015
- 2015-07-02 BR BR112016030950A patent/BR112016030950A2/pt not_active Application Discontinuation
- 2015-07-02 CN CN201580036900.4A patent/CN106659771B/zh active Active
- 2015-07-02 WO PCT/AU2015/050369 patent/WO2016000039A1/en active Application Filing
- 2015-07-02 AU AU2015283822A patent/AU2015283822B2/en active Active
- 2015-07-02 ES ES15814529T patent/ES2844232T3/es active Active
- 2015-07-02 JP JP2016576005A patent/JP6676551B2/ja active Active
- 2015-07-02 US US15/323,401 patent/US10253088B2/en active Active
- 2015-07-02 DK DK15814529.2T patent/DK3164150T3/da active
- 2015-07-02 EP EP15814529.2A patent/EP3164150B1/en active Active
- 2015-07-02 CA CA2953593A patent/CA2953593C/en active Active
- 2015-07-02 KR KR1020177002860A patent/KR20170026580A/ko not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| AU2015283822B2 (en) | 2019-10-03 |
| CN106659771A (zh) | 2017-05-10 |
| CN106659771B (zh) | 2021-09-24 |
| CA2953593A1 (en) | 2016-01-07 |
| CA2953593C (en) | 2023-09-26 |
| JP6676551B2 (ja) | 2020-04-08 |
| KR20170026580A (ko) | 2017-03-08 |
| ES2844232T3 (es) | 2021-07-21 |
| US10253088B2 (en) | 2019-04-09 |
| US20170152300A1 (en) | 2017-06-01 |
| EP3164150A1 (en) | 2017-05-10 |
| EP3164150B1 (en) | 2020-11-04 |
| EP3164150A4 (en) | 2018-03-07 |
| WO2016000039A1 (en) | 2016-01-07 |
| DK3164150T3 (da) | 2021-02-08 |
| JP2017521070A (ja) | 2017-08-03 |
| AU2015283822A1 (en) | 2017-01-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112016030950A2 (pt) | polipeptídeo modificado que se liga ao fator viii, complexo, composição farmacêutica, métodos para tratar uma coagulopatia, para produzir um polipeptídeo que compreende um vwf modificado e para aumentar a afinidade de ligação ao fator viii do vwf e a meia-vida do fator viii, uso de um polipeptídeo modificado ou de um complexo, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira. | |
| CL2021000519A1 (es) | (divisional de solicitud 732-2018) anticuerpo anti-vegf y su uso en el tratamiento de la angiogénesis patológica. | |
| CL2021000716A1 (es) | Constructos de anticuerpo para flt3 y cd3. (divisional sol. 201800269) | |
| BR112017003194B8 (pt) | Anticorpo ou fragmento de ligação ao antígeno do mesmo que se liga especificamente a lag3 humano, composição, e, uso do anticorpo ou de um fragmento de ligação ao antígeno do mesmo e da composição | |
| PH12018501250A1 (en) | Chimeric factor viii polypeptides and uses thereof | |
| BR112017003582A2 (pt) | anticorpos, composições e usos | |
| BR112017024610A2 (pt) | anticorpos para receptor antitransferrina com afinidade especificada | |
| BR112018074325A2 (pt) | anticorpo para ligação a receptor de interleucina 4 | |
| PE20180480A1 (es) | Anticuerpos de factor xi y metodos de uso | |
| BR112017013274A2 (pt) | polipeptídeo e imunomodulação | |
| BR112017004949A2 (pt) | receptor do antígeno quimérico, polinucleotídeo, vetor, célula, e, composição farmacêutica. | |
| BR112016014810A2 (pt) | Antagonistas de fcrn e métodos de uso | |
| SG10201909716RA (en) | Modified j-chain | |
| BR112018077375A2 (pt) | kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente | |
| BR112018013822A2 (pt) | ?polipeptídeo modificado, complexo, composição farmacêutica, métodos para tratamento de um distúrbio hemorrágico, para produção de um polipeptídeo e para aumento da meia-vida do fator viii, uso de um polipeptídeo modificado, polinucleotídeo, plasmídeo ou vetor, e, célula hospedeira? | |
| NZ761188A (en) | Antibody molecules to tim-3 and uses thereof | |
| MX2018005399A (es) | Nuevo polipeptido con afinidad por pd-l1. | |
| BR112016029318A2 (pt) | tratamento de mielomas | |
| BR112019023071A2 (pt) | proteínas de fusão do receptor tgf-beta do tipo ii e uso das mesmas | |
| PH12017502190A1 (en) | T-cell receptor specific antibodies | |
| BR112018011059A2 (pt) | synp161, um promotor para a expressão específica de genes em fotoreceptores de haste | |
| MX2015016814A (es) | Anticuerpo anti-tweakr y sus usos. | |
| MX2017000083A (es) | Compuestos de platino, composiciones y usos de estos. | |
| BR112018067951A2 (pt) | moléculas que se ligam a ilt7 e métodos de uso destas | |
| SG10201909816PA (en) | Methods of polynucleotide preparation using multivalent cation salt compositions |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NAO 10196/2001, QUE MODIFICOU A LEI NAO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUAANCIA PRA VIA DA ANVISA. CONSIDERANDO A APROVAA AO DOS TERMOS DO PARECER NAO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NAO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDAANCIAS CABA-VEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06U | Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 5A ANUIDADE. |
|
| B11B | Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements |